{"entity":{"id":"nct05583552","kind":"trial","name":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy","aka":["IMpress"],"tldr":"A phase 2 trial of Imetelstat in myelodysplastic syndromes / neoplasms and acute myeloid leukaemia, run by GCP-Service International West GmbH, active and no longer recruiting.","summary":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy is a phase 2 interventional study registered as NCT05583552 by GCP-Service International West GmbH, with 46 participants enrolled, started 2023-06-05 and due to reach its primary completion in 2025-03-27. Interventions recorded: Imetelstat sodium. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05583552","url":"https://clinicaltrials.gov/study/NCT05583552"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mds","aml","mds-higher-risk"],"sections":[],"technologies":["antisense-sirna"],"targets":[],"drugs":["imetelstat"],"companies":["geron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05583552","phase":"2","setting":"A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy","sponsor":"GCP-Service International West GmbH","started":"2023-06-05","startedType":"actual","yearReported":2026,"enrolled":46,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Hematological Response Rate of Participants After Treatment With Imetelstat","primary":true,"unit":"participants","arms":[{"name":"Imetelstat Sodium (1 Treatment / Cycle)","n":23,"value":0,"note":"Figures from the ClinicalTrials.gov results section (first posted 2026-05-12), not from a publication"},{"name":"Imetelstat Sodium (2 Treatments / Cycle)","n":23,"value":1}],"source":"https://clinicaltrials.gov/study/NCT05583552?tab=results"}]},"route":"/trials/nct05583552/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"technology":[{"id":"antisense-sirna","kind":"technology","name":"Oligonucleotide therapeutics","route":"/technologies/antisense-sirna/"}],"drug":[{"id":"imetelstat","kind":"drug","name":"Imetelstat","route":"/drugs/imetelstat/"}],"company":[{"id":"geron","kind":"company","name":"Geron Corporation","route":"/companies/geron/"}]}}